Published • loading... • Updated
UK begins trials of Ebola vaccine developed in just eight weeks
The early-stage trial will test safety and immune response in 50 healthy adults as researchers race to address an outbreak in Congo and Uganda.
- On Monday, the University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to combat the outbreak spreading in the Democratic Republic of Congo and Uganda.
- The Bundibugyo species has caused two previous outbreaks and currently spreads through Congo, where confirmed cases rose to 1,926, including 702 deaths, the country's public health institute said on Monday.
- Scientists at the Oxford Vaccine Group and Pandemic Sciences Institute developed the shot using the same viral vector platform as the AstraZeneca Covid vaccine; the Serum Institute of India stockpiled around 620,000 doses.
- The early-stage trial, known as BD-Ebov, will evaluate safety and immune response in 50 healthy adults aged 18 to 55, with The Coalition for Epidemic Preparedness Innovations investing up to $8.6 million.
- Chief investigator Dr. Katrina Pollock noted that Ebola species are "sisters rather than twins," requiring distinct vaccines; researchers plan further clinical studies in Uganda with year-long volunteer monitoring.
Insights by Ground AI
33 Articles
33 Articles
UK Begins Human Trials of New Ebola Vaccine in Just 57 Days as Scientists Race to Stop Deadly Virus
Human trials of an experimental Ebola vaccine have begun in the UK just 57 days after development began, making it one of the fastest vaccine responses since the Covid-19 pandemic. Researchers at the University of Oxford say the rapid timeline was possible because they adapted the same ChAdOx1 platform that underpinned the Oxford-AstraZeneca Covid vaccine. The vaccine was created in response to the Bundibugyo strain of Ebola, which is causing an…
·United Kingdom
Read Full Article
Coverage Details
Total News Sources33
Leaning Left8Leaning Right4Center8Last UpdatedBias Distribution40% Left, 40% Center
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
40% Center
L 40%
C 40%
R 20%
Factuality
To view factuality data please Upgrade to Premium
